Cytogenix And Baylor College of Medicine to Conduct Pre-Clinical Testing Of An Aerosol Gene-Silencing Agent Against Cancer In The Lung
HOUSTON--(BUSINESS WIRE)--Jan. 21, 2004--CytoGenix Inc. (OTCBB:CYGX - News) has entered into an agreement with scientists at Baylor College of Medicine for experiments using a combination of the company's ssDNA expression vector technology and Baylor's proprietary aerosol gene delivery technology against a gene that, when silenced, inhibits tumor metastasis.
Dr. Charles L. Densmore, assistant professor, department of molecular physiology and biophysics, will direct these studies to determine the effect this novel gene delivery and silencing system has on cancer in the lungs of mice. Dr. Densmore is the inventor of this aerosol gene delivery system. He has pioneered its use for lung cancer, asthma and other pulmonary disorders.
Dr. Densmore stated, "The combination of these technologies has great potential for treating metastatic lung cancers and other difficult to treat pulmonary disorders. Our aerosol technology is non-invasive, and delivers directly to airway epithelial and pulmonary surfaces, thus avoiding many of the problems associated with intravenous delivery such as interaction with serum proteins, and difficulties in penetrating lung endothelial barriers."
Dr. Malcolm Skolnick, chairman and CEO of CytoGenix, stated, "We are very excited about the potential development of a very important clinical application of our ssDNA expression vector. Metastatic lung tumors are important targets because several cancers such as melanoma, breast and prostate tend to metastasize in the lungs."
CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the Web site at www.cytogenix.com.
Contact:
CytoGenix, Houston Juan Ferreira, 407-774-9949
Source
